NPC
MCID: NSP012
MIFTS: 66

Nasopharyngeal Carcinoma (NPC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Oral diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Nasopharyngeal Carcinoma

MalaCards integrated aliases for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma 56 12 74 52 58 29 13 54 6 15 39 71
Malignant Neoplasm of Nasopharynx 12 71 32
Nasopharyngeal Cancer 56 52 36
Nasopharyngeal Neoplasms 43 71
Nasopharynx Carcinoma 12 15
Npc 56 17
Squamous Cell Carcinoma of the Nasopharynx 58
Malignant Nasopharyngeal Tumor 12
Nasopharyngeal Carcinoma 1 56
Carcinoma of Nasopharynx 12
Nasopharyngeal Neoplasm 17
Cancer of Nasopharynx 71
Nasopharynx Cancer 12
Npca 56

Characteristics:

Orphanet epidemiological data:

58
nasopharyngeal carcinoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

HPO:

31
nasopharyngeal carcinoma:
Inheritance polygenic inheritance


Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:9261
OMIM 56 607107
KEGG 36 H00054
MeSH 43 D009303
NCIt 49 C9321
MESH via Orphanet 44 C538339
ICD10 via Orphanet 33 C11.0 C11.1 C11.2 more
UMLS via Orphanet 72 C0153392 C0238301 C2931822
Orphanet 58 ORPHA150
MedGen 41 C2931822
SNOMED-CT via HPO 68 126680004
UMLS 71 C0027439 C0153392 C0153393 more

Summaries for Nasopharyngeal Carcinoma

KEGG : 36 Nasopharyngeal carcinoma (NPC) is a rare disease in most parts of the world, with an age-standardised annual incidence of less than 1 per 100000. However, in Southern China, parts of Southeast Asia and the Mediterranean basin, NPC is an endemic disease with an incidence of 10-30 per 100000. Genome-wide studies have unravelled multiple chromosomal abnormalities with involvement of specific oncogenes and tumor suppressor genes. Alterations of genes such as Ras association domain family 1A (RASSF1A), p16/INK4A, p14/ARF suggest that multiple cellular pathways were dysregulated in the NPC cells. Studies on the precancerous lesions revealed early genetic changes and a critical role of Epstein- Barr virus (EBV) latent infection in the development of this cancer.

MalaCards based summary : Nasopharyngeal Carcinoma, also known as malignant neoplasm of nasopharynx, is related to squamous cell carcinoma and b-cell lymphoma, and has symptoms including headache, tinnitus and rhinorrhea. An important gene associated with Nasopharyngeal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Erythromycin and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, t cells and bone, and related phenotype is neoplasia of the nasopharynx.

Disease Ontology : 12 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or throat, where the nasal passages and auditory tubes join the remainder of the upper respiratory tract.

OMIM : 56 Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx. The Epstein-Barr virus has been implicated (Tse et al., 2009). (607107)

Wikipedia : 74 Nasopharyngeal carcinoma (NPC), or nasopharynx cancer, is the most common cancer originating in the... more...

Related Diseases for Nasopharyngeal Carcinoma

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 2 Nasopharyngeal Carcinoma 3

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 683)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.8 TP53 PIK3CA NEAT1 HRAS HOTAIR FOXCUT
2 b-cell lymphoma 31.8 TP53 PVT1 NFKBIA HOTAIR GAS5
3 in situ carcinoma 31.8 TP53 PIK3CA HRAS
4 osteogenic sarcoma 31.7 XIST TP53 PVT1 NEAT1 HOTAIR GAS5
5 squamous cell papilloma 31.6 TP53 HRAS
6 sarcoma 31.5 TP53 PIK3CA NRAS HRAS HOTAIR
7 esophageal cancer 31.4 XIST TP53 PVT1 PIK3CA MIR100 LINC00460
8 squamous cell carcinoma, head and neck 31.4 TP53 PIK3CA NFKBIA MIR29C HRAS HOTAIR
9 thyroid carcinoma 31.3 PIK3CA NEAT1 HRAS
10 oropharynx cancer 31.3 TP53 PIK3CA HRAS
11 retinitis pigmentosa 11 31.2 XIST TP53 PVT1 NEAT1 HRAS HOTAIR
12 cervical cancer 31.2 TP53 PVT1 PIK3CA NPTN-IT1 NEAT1 HRAS
13 bladder cancer 31.1 XIST TP53 PVT1 PIK3CA NRAS MIR29C
14 hepatocellular carcinoma 31.1 XIST TP53 PVT1 PIK3CA NRAS NPTN-IT1
15 laryngeal squamous cell carcinoma 31.1 TP53 NEAT1 HOTAIR CDKN2B-AS1
16 neuroblastoma 31.0 TP53 PIK3CA NRAS NFKBIA MIR29C HRAS
17 lung cancer susceptibility 3 31.0 TP53 PIK3CA NRAS NPTN-IT1 MIR29C LINC-ROR
18 oral squamous cell carcinoma 31.0 TP53 NEAT1 MIR100 HRAS HOTAIR FOXCUT
19 breast cancer 31.0 XIST TP53 PVT1 PIK3CA NRAS NEAT1
20 lung cancer 30.9 XIST TP53 PVT1 PIK3CA NRAS NFKBIA
21 renal cell carcinoma, nonpapillary 30.9 TP53 PVT1 PIK3CA NRAS NPTN-IT1 MIR29C
22 astrocytoma 30.9 PVT1 NEAT1 HOTAIR GAS5 CDKN2B-AS1
23 leukemia 30.8 TP53 NRAS NEAT1 HRAS HOTAIR GAS5
24 glioma 30.8 TP53 PVT1 PIK3CA NEAT1 HOTAIR GAS5
25 mantle cell lymphoma 30.8 TP53 PIK3CA NFKBIA GAS5
26 lung squamous cell carcinoma 30.8 TP53 PVT1 PIK3CA NPTN-IT1 HRAS
27 thyroid gland cancer 30.7 TP53 PVT1 PIK3CA NRAS LINC00312 HRAS
28 thyroid cancer, nonmedullary, 1 30.7 NEAT1 LINC-ROR HOTAIR
29 malignant glioma 30.7 XIST TP53 PVT1 NEAT1 LINC-ROR HOTAIR
30 leukemia, acute myeloid 30.7 TP53 PIK3CA NRAS HRAS HOTAIR CDKN2B-AS1
31 ovarian cancer 30.7 XIST TP53 PVT1 PIK3CA NFKBIA NEAT1
32 colorectal cancer 30.6 XIST TP53 PVT1 PIK3CA NRAS NPTN-IT1
33 leukemia, chronic myeloid 30.6 TP53 NRAS NFKBIA HRAS HOTAIR
34 prostate cancer 30.6 XIST TP53 PVT1 PIK3CA NFKBIA NEAT1
35 acute promyelocytic leukemia 30.6 TP53 PVT1 PIK3CA NRAS NEAT1 HRAS
36 myeloma, multiple 30.6 TP53 PVT1 NRAS NFKBIA HRAS HOTAIR
37 nasopharyngeal carcinoma 3 12.8
38 nasopharyngeal carcinoma 2 12.8
39 niemann-pick disease, type c1 12.3
40 lymphoepithelioma-like carcinoma 11.7
41 female reproductive endometrioid cancer 10.9 TP53 PIK3CA HRAS
42 anus cancer 10.9 TP53 PIK3CA HRAS
43 epithelial-myoepithelial carcinoma 10.9 TP53 PIK3CA HRAS
44 myoepithelial carcinoma 10.9 TP53 PIK3CA HRAS
45 uterine body mixed cancer 10.9 TP53 PIK3CA HRAS
46 mixed cell type cancer 10.9 TP53 PIK3CA HRAS
47 mucositis 10.9
48 rectum adenocarcinoma 10.9 TP53 PIK3CA HRAS
49 uterine corpus endometrial carcinoma 10.9 TP53 PIK3CA HRAS
50 ovarian cystadenocarcinoma 10.9 TP53 PIK3CA HRAS

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:



Diseases related to Nasopharyngeal Carcinoma

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

Human phenotypes related to Nasopharyngeal Carcinoma:

31
# Description HPO Frequency HPO Source Accession
1 neoplasia of the nasopharynx 31 HP:0100630

Clinical features from OMIM:

607107

UMLS symptoms related to Nasopharyngeal Carcinoma:


headache, tinnitus, rhinorrhea

Drugs & Therapeutics for Nasopharyngeal Carcinoma

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 355)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
tannic acid Approved Phase 4 1401-55-4
8
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
9 Anti-Infective Agents Phase 4
10 Anti-Bacterial Agents Phase 4
11 Gastrointestinal Agents Phase 4
12 Erythromycin Estolate Phase 4
13 Erythromycin stearate Phase 4
14 Erythromycin Ethylsuccinate Phase 4
15 Liver Extracts Phase 4
16 Psychotropic Drugs Phase 4
17 Cytochrome P-450 Enzyme Inhibitors Phase 4
18 Neurotransmitter Agents Phase 4
19 Cholinergic Agents Phase 4
20 Central Nervous System Stimulants Phase 4
21 Antidepressive Agents Phase 4
22 Nicotinic Agonists Phase 4
23 Dopamine Agents Phase 4
24 Anesthetics Phase 4
25 Narcotics Phase 4
26 Anesthetics, General Phase 4
27 Analgesics, Opioid Phase 4
28 Anesthetics, Intravenous Phase 4
29 Cyclooxygenase 2 Inhibitors Phase 4
30
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
31
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
32
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
33
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
34
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
35
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
36
Promethazine Approved, Investigational Phase 3 60-87-7 4927
37
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
38
Histamine Approved, Investigational Phase 3 51-45-6 774
39
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
40
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
41
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
42
Fluticasone Approved, Experimental Phase 3 90566-53-3 62924
43
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
44
Oprelvekin Approved, Investigational Phase 3 145941-26-0
45
Budesonide Approved Phase 3 51333-22-3 63006 5281004
46
Acyclovir Approved Phase 3 59277-89-3 2022
47
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
48 Benralizumab Approved, Investigational Phase 3 1044511-01-4
49
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
50
Gemcitabine Approved Phase 3 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 754)
# Name Status NCT ID Phase Drugs
1 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
2 Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury After Therapy With Docetaxel and Cisplatin for Nasopharyngeal Carcinoma Unknown status NCT03069820 Phase 4 docetaxel and cisplatin
3 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
4 Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough. Unknown status NCT02175914 Phase 4 Erythromycin
5 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
6 Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx Completed NCT00772681 Phase 4 docetaxel and cisplatin
7 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
8 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
9 A Prospective, Randomized Controlled Open Research About the Impact of Nutritional Support on the Radiation Tolerance and Clinical Outcomes for Local Advanced Nasopharyngeal Carcinoma Patients Active, not recruiting NCT02948699 Phase 4
10 A Comparison of Oral Controlled-release Morphine With Transdermal Fentanyl in Nasopharyngeal Cancer Patients With Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy Not yet recruiting NCT04292990 Phase 4 Fentanyl;Morphine
11 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP) Terminated NCT00140894 Phase 4 MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
12 Standard Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Adjuvant Chemotherapy for Locally Advanced (Non-Metastatic) Nasopharyngeal Cancer Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
13 A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
14 A Randomized, Multicenter Phase III Clinical Trial Comparing Gemcitabine and Cisplatin With 5-Fluorouracil and Cisplatin in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Unknown status NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
15 Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
16 The Effect of Celecoxib on Concurrent Chemoradiation With Weekly Nedaplatin in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
17 A Randomized Phase III Study of Concurrent Weekly Nedaplatin or Cisplatin With IMRT in NPC Patients Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
18 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
19 A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) Unknown status NCT02907710 Phase 3 Endostar;DDP
20 A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage Ⅲ Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
21 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated Radiotherapy With or Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
22 Cisplatin and 5-fluorouracil(PF) or Docetaxel,Cisplatin and 5-fluorouracil (TPF) Neoadjuvant Chemotherapy With Chemoradiation Therapy for Locally Advanced Nasopharyngeal Carcinoma--A Randomised Prospective Multicenter Phase 3 Study Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
23 Fine Needle Aspiration of Retropharyngeal Lymph Node Guided by Endoscopic Ultrasound for the Diagnosis of Patients With Suspected Recurrent Nasopharyngeal Carcinoma Unknown status NCT03006588 Phase 2, Phase 3
24 Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
25 A Multicenter Trial Comparing Neoadjuvant Chemotherapy Followed by CCRT v.s. CCRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
26 A Multicenter Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
27 A Multicenter Trial Evaluating the Efficacy and Safety of Nedaplatin Plus Docetaxel in Neoadjuvant Chemotherapy Followed by Nedaplatin in Concurrent Chemoradiation for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
28 A Randomized Phase III Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
29 MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE. Unknown status NCT00180973 Phase 3 Hydroxyurea
30 Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Following High-dose Cisplatin in Nasopharyngeal Carcinoma Patients:a Randomized Phase 3 Trial Unknown status NCT02933099 Phase 3 Aprepitant+palonosetron+dexamethasone;palonosetron+dexamethasone
31 A Pilot Study to Investigate the Efficacy and Safety of Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis (CRS) With Polyposis Nasi in Adult Patients Unknown status NCT01946711 Phase 3 Budesonide;Budesonide
32 A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
33 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
34 Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
35 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
36 A Comparison of Acute Oral Mucositis Between Morning and Afternoon Radiotherapy in Patients Receiving Radiation Treatment for Cancer of the Head and Neck Completed NCT00004234 Phase 3
37 RADIATION WITH MITOMYCIN C OR PORFIROMYCIN IN THE TREATMENT OF CANCER OF THE HEAD AND NECK AREA Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
38 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
39 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
40 Phase III Randomized Trial of Methotrexate vs. Paclitaxel in Cisplatin-Ineligible Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00003592 Phase 3 methotrexate;paclitaxel
41 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
42 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
43 Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
44 Phase III Trial of Low-level Laser Therapy to Prevent Induced Oral Mucositis in Head and Neck Cancer Patients Submitted to Concurrent Chemoradiation Completed NCT01439724 Phase 3
45 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
46 A Phase III Study to Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Completed NCT00535795 Phase 3
47 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
48 Late-Course Accelerated Hyperfractionated IMRT Versus Conventionally Fractionated IMRT in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Clinical Trial Completed NCT00778908 Phase 2, Phase 3 Concomitant cisplatin chemotherapy
49 A Randomized Phase III Non-inferiority Study of Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
50 Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy With Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC). Completed NCT02012062 Phase 3 TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Genetic Tests for Nasopharyngeal Carcinoma

Genetic tests related to Nasopharyngeal Carcinoma:

# Genetic test Affiliating Genes
1 Nasopharyngeal Carcinoma 29 TP53

Anatomical Context for Nasopharyngeal Carcinoma

MalaCards organs/tissues related to Nasopharyngeal Carcinoma:

40
Lymph Node, T Cells, Bone, Lung, Brain, Breast, Testes

Publications for Nasopharyngeal Carcinoma

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 13969)
# Title Authors PMID Year
1
An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. 56 6 61
1631151 1992
2
Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. 6 61
26951679 2016
3
The genomic landscape of nasopharyngeal carcinoma. 61 56
24952746 2014
4
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. 56 61
20512145 2010
5
Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. 56 61
19664746 2009
6
A functional variant in the transcriptional regulatory region of gene LOC344967 cosegregates with disease phenotype in familial nasopharyngeal carcinoma. 61 56
16423998 2006
7
Association of PLUNC gene polymorphisms with susceptibility to nasopharyngeal carcinoma in a Chinese population. 56 61
15689457 2005
8
A rare polymorphism of the COX7B2 gene in a Cantonese family with nasopharyngeal carcinoma. 56 61
15623157 2004
9
Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. 56 61
12118254 2002
10
Familial nasopharyngeal carcinoma. 56 61
6609336 1984
11
Familial clustering of nasopharyngeal carcinoma. 56 61
7191767 1980
12
Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. 46 61
19739117 2010
13
Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from southeastern Asia. 56
7729941 1995
14
Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. 61 54
20124221 2010
15
Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. 61 54
20398418 2010
16
[Tumor-targeted human telomerase reverse transcriptase promoter/tk gene therapy against human nasopharyngeal carcinoma cells in vitro]. 54 61
20423828 2010
17
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. 54 61
20053927 2010
18
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. 61 54
20412566 2010
19
Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. 61 54
20338061 2010
20
Indole-3-carbinol inhibits nasopharyngeal carcinoma. 54 61
20335513 2010
21
Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. 54 61
20036222 2010
22
[Study on the relationship between TK gene regulated by enhanced suicide gene vector and telomerase activity in nasopharyngeal carcinoma cells]. 54 61
20422982 2010
23
Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells. 61 54
20109337 2010
24
Bax inhibitor-1 mediates apoptosis-resistance in human nasopharyngeal carcinoma cells. 54 61
19579059 2010
25
Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. 54 61
19628018 2010
26
Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. 54 61
19816982 2009
27
Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. 54 61
20042089 2009
28
A case-control and a family-based association study revealing an association between CYP2E1 polymorphisms and nasopharyngeal carcinoma risk in Cantonese. 54 61
19805575 2009
29
PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. 61 54
19735264 2009
30
[Expression of HSP70/HSP27 protein in residual lesion after NPC radiotherapy]. 61 54
19952398 2009
31
[Induced RAS association domain family gene 1A gene expression by arsenic trioxide in nasopharyngeal carcinoma cell]. 54 61
20079060 2009
32
LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells. 54 61
19860880 2009
33
[Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression]. 54 61
20387494 2009
34
Role of p38 MAPKs in hypericin photodynamic therapy-induced apoptosis of nasopharyngeal carcinoma cells. 54 61
19496992 2009
35
Regulation of RASSF1A in nasopharyngeal cells and its response to UV irradiation. 54 61
19450668 2009
36
IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients. 54 61
19551836 2009
37
ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. 54 61
19698176 2009
38
[The relationship between the expression of EGFR NF-kappaB and radiosensitivity in human nasopharyngeal carcinoma]. 54 61
19947250 2009
39
[Association of nasopharyngeal carcinoma risk with cytochrome P450 CYP1A1 gene polymorphisms]. 54 61
19954069 2009
40
[Expression of E-cadherin and P(120ctn) in nasopharyngeal carcinoma and their relationship]. 54 61
19894558 2009
41
[Matrine enhances the cytotoxic sensitivity of ABCG2high nasopharyngeal carcinoma cells to natural killer cells by inducing high expression of NKG2D receptor ligands]. 61 54
19620045 2009
42
Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. 61 54
19429479 2009
43
Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma. 61 54
19360294 2009
44
Curcuminoids suppress the growth of pharynx and nasopharyngeal carcinoma cells through induced apoptosis. 61 54
19317462 2009
45
GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysis. 61 54
19338664 2009
46
[Association of CXCR4 and SDF-1alpha with organ-specific metastasis of nasopharyngeal carcinoma]. 61 54
19615279 2009
47
Nasopharyngeal carcinoma in Brunei Darussalam: low incidence among the Chinese and an evaluation of antibodies to Epstein-Barr virus antigens as biomarkers. 54 61
19421680 2009
48
Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. 61 54
19132724 2009
49
Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. 54 61
19221469 2009
50
Dual silencing of epidermal growth factor and insulin-like growth factor 1 receptors significantly limits growth of nasopharyngeal carcinoma in nude mice. 61 54
18452630 2009

Variations for Nasopharyngeal Carcinoma

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

6 (show all 37) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
2 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
3 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His)SNV Pathogenic 12374 rs28934578 17:7578406-7578406 17:7675088-7675088
4 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
5 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
6 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
7 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
8 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
9 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
10 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
11 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
12 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
13 TP53 NM_001126112.2(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
14 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic/Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
15 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
16 TP53 NM_001126112.2(TP53):c.799C>T (p.Arg267Trp)SNV Pathogenic/Likely pathogenic 141764 rs55832599 17:7577139-7577139 17:7673821-7673821
17 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)SNV Pathogenic/Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
18 TP53 NM_001126112.2(TP53):c.638G>C (p.Arg213Pro)SNV Pathogenic/Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
19 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)SNV Pathogenic/Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304
20 TP53 NM_001126112.2(TP53):c.559+1G>ASNV Pathogenic/Likely pathogenic 428908 rs1131691042 17:7578370-7578370 17:7675052-7675052
21 TP53 NM_001126112.2(TP53):c.96+1G>TSNV Pathogenic/Likely pathogenic 482212 rs1131691003 17:7579699-7579699 17:7676381-7676381
22 FGFR2 NM_000141.5(FGFR2):c.1647T>A (p.Asn549Lys)SNV Likely pathogenic 376157 rs121913476 10:123258034-123258034 10:121498520-121498520
23 FGFR2 NM_000141.5(FGFR2):c.1914T>A (p.Asn638Lys)SNV Likely pathogenic 376315 rs1057519854 10:123247577-123247577 10:121488063-121488063
24 FGFR2 NM_000141.5(FGFR2):c.1642A>C (p.Ile548Leu)SNV Likely pathogenic 376433 rs1057519901 10:123258039-123258039 10:121498525-121498525
25 FGFR2 NM_000141.5(FGFR2):c.1645A>C (p.Asn549His)SNV Likely pathogenic 374821 rs1057519045 10:123258036-123258036 10:121498522-121498522
26 TP53 NM_001126112.2(TP53):c.638G>T (p.Arg213Leu)SNV Likely pathogenic 376650 rs587778720 17:7578211-7578211 17:7674893-7674893
27 TP53 NM_001126112.2(TP53):c.637C>G (p.Arg213Gly)SNV Likely pathogenic 376651 rs397516436 17:7578212-7578212 17:7674894-7674894
28 TP53 NM_001126112.2(TP53):c.839G>A (p.Arg280Lys)SNV Conflicting interpretations of pathogenicity 376657 rs121912660 17:7577099-7577099 17:7673781-7673781
29 TP53 NM_001126112.2(TP53):c.838A>G (p.Arg280Gly)SNV Conflicting interpretations of pathogenicity 376658 rs753660142 17:7577100-7577100 17:7673782-7673782
30 TP53 NM_001126112.2(TP53):c.523C>T (p.Arg175Cys)SNV Conflicting interpretations of pathogenicity 245851 rs138729528 17:7578407-7578407 17:7675089-7675089
31 NRAS NM_002524.5(NRAS):c.181C>A (p.Gln61Lys)SNV Conflicting interpretations of pathogenicity 73058 rs121913254 1:115256530-115256530 1:114713909-114713909
32 TP53 NM_001126112.2(TP53):c.466C>T (p.Arg156Cys)SNV Conflicting interpretations of pathogenicity 127810 rs563378859 17:7578464-7578464 17:7675146-7675146
33 TP53 NM_000546.6(TP53):c.847C>T (p.Arg283Cys)SNV Uncertain significance 127824 rs149633775 17:7577091-7577091 17:7673773-7673773
34 TP53 NM_001126112.2(TP53):c.461G>A (p.Gly154Asp)SNV Uncertain significance 237950 rs762846821 17:7578469-7578469 17:7675151-7675151
35 TP53 NM_001126112.2(TP53):c.839G>T (p.Arg280Ile)SNV Uncertain significance 161517 rs121912660 17:7577099-7577099 17:7673781-7673781
36 TP53 NM_001126112.2(TP53):c.839G>C (p.Arg280Thr)SNV Uncertain significance 12368 rs121912660 17:7577099-7577099 17:7673781-7673781
37 TP53 NM_001126112.2(TP53):c.760A>G (p.Ile254Val)SNV Uncertain significance 406605 rs746601313 17:7577521-7577521 17:7674203-7674203

Cosmic variations for Nasopharyngeal Carcinoma:

9 (show top 50) (show all 195)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87898351 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 4
2 COSM135128838 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1259C>T p.S420F 9:99146601-99146601 4
3 COSM84678061 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 4
4 COSM86828717 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 4
5 COSM94496058 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 4
6 COSM97061657 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
7 COSM97061670 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 4
8 COSM101904169 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 4
9 COSM101917565 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 4
10 COSM101909541 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 4
11 COSM135344063 PLCG2 skin,neck,carcinoma,squamous cell carcinoma c.115G>T p.E39* 16:81786104-81786104 4
12 COSM96446251 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.310G>A p.G104R 7:106867871-106867871 4
13 COSM96446257 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.3227G>A p.R1076K 7:106905305-106905305 4
14 COSM97107379 NRAS skin,neck,carcinoma,squamous cell carcinoma c.35G>A p.G12D 1:114716126-114716126 4
15 COSM96979266 NCOA3 skin,neck,carcinoma,squamous cell carcinoma c.979C>T p.H327Y 20:47634062-47634062 4
16 COSM94433642 MTOR skin,neck,carcinoma,squamous cell carcinoma c.3409G>A p.E1137K 1:11212464-11212464 4
17 COSM88433397 KMT2C skin,neck,carcinoma,squamous cell carcinoma c.11659C>T p.H3887Y 7:152158874-152158874 4
18 COSM129134015 KMT2A skin,neck,carcinoma,squamous cell carcinoma c.4377T>G p.C1459W 11:118488658-118488658 4
19 COSM112988842 HRAS skin,neck,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 11:533874-533874 4
20 COSM87850134 HGF skin,neck,carcinoma,squamous cell carcinoma c.974C>T p.P325L 7:81729671-81729671 4
21 COSM97161142 FUBP1 skin,neck,carcinoma,squamous cell carcinoma c.430C>T p.P144S 1:77966737-77966737 4
22 COSM90925428 FGFR3 skin,neck,carcinoma,squamous cell carcinoma c.2427A>G p.*809Wext*101 4:1807262-1807262 4
23 COSM113064666 FGFR2 skin,neck,carcinoma,squamous cell carcinoma c.2237C>T p.S746F 10:121483765-121483765 4
24 COSM96350412 EPHA7 skin,neck,carcinoma,squamous cell carcinoma c.2468G>A p.G823E 6:93254711-93254711 4
25 COSM143839996 EPHA5 skin,neck,carcinoma,squamous cell carcinoma c.2611G>A p.E871K 4:65348104-65348104 4
26 COSM90880957 EPHA3 skin,neck,carcinoma,squamous cell carcinoma c.533G>A p.G178E 3:89210239-89210239 4
27 COSM90896216 EPHA3 skin,neck,carcinoma,squamous cell carcinoma c.632T>A p.M211K 3:89210338-89210338 4
28 COSM94452739 CASP8 skin,neck,carcinoma,squamous cell carcinoma c.1508C>T p.T503I 2:201286485-201286485 4
29 COSM94447474 CASP8 skin,neck,carcinoma,squamous cell carcinoma c.1219C>T p.L407F 2:201285055-201285055 4
30 COSM88124807 ATM skin,neck,carcinoma,squamous cell carcinoma c.1009C>T p.R337C 11:108247071-108247071 4
31 COSM88887524 APC skin,neck,carcinoma,squamous cell carcinoma c.536C>T p.S179F 5:112780794-112780794 4
32 COSM86931984 AKT3 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 4
33 COSM143943797 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 4
34 COSM151006887 skin,neck,carcinoma,squamous cell carcinoma c.974C>T p.P325L 7:81729671-81729671 4
35 COSM87854487 skin,neck,carcinoma,squamous cell carcinoma c.1079C>T p.T360I 2:201286485-201286485 4
36 COSM90842417 skin,neck,carcinoma,squamous cell carcinoma c.11659C>T p.H3887Y 7:152158874-152158874 4
37 COSM142560281 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 4
38 COSM94156150 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 4
39 COSM101967270 skin,neck,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 11:533874-533874 4
40 COSM96948694 skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
41 COSM144087106 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 4
42 COSM125447871 skin,neck,carcinoma,squamous cell carcinoma c.2611G>A p.E871K 4:65348104-65348104 4
43 COSM96966855 skin,neck,carcinoma,squamous cell carcinoma c.1009C>T p.H337Y 20:47634062-47634062 4
44 COSM97161923 skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
45 COSM92783540 skin,neck,carcinoma,squamous cell carcinoma c.997C>T p.L333F 2:201285055-201285055 4
46 COSM133256111 skin,neck,carcinoma,squamous cell carcinoma c.1040C>T p.S347F 9:99146601-99146601 4
47 COSM144310203 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 4
48 COSM96619514 skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 4
49 COSM92948518 skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 4
50 COSM142837352 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 4

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

7 (show all 41)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 72234 12 7764270 8036678 Duplication CLEC4C Nasopharyngeal cancer
2 72235 12 7764270 8036678 Duplication NANOG Nasopharyngeal cancer
3 72236 12 7764270 8036678 Duplication NANOGNB Nasopharyngeal cancer
4 72237 12 7764270 8036678 Duplication SLC2A14 Nasopharyngeal cancer
5 72238 12 7764270 8036678 Duplication SLC2A3 Nasopharyngeal cancer
6 126614 19 19848080 20497256 Deletion MIR1270-1 Nasopharyngeal cancer
7 126615 19 19848080 20497256 Deletion MIR1270-2 Nasopharyngeal cancer
8 126616 19 19848080 20497256 Deletion ZNF253 Nasopharyngeal cancer
9 126617 19 19848080 20497256 Deletion ZNF486 Nasopharyngeal cancer
10 126618 19 19848080 20497256 Deletion ZNF682 Nasopharyngeal cancer
11 126619 19 19848080 20497256 Deletion ZNF826P Nasopharyngeal cancer
12 126620 19 19848080 20497256 Deletion ZNF90 Nasopharyngeal cancer
13 126621 19 19848080 20497256 Deletion ZNF93 Nasopharyngeal cancer
14 132647 19 59423491 59445355 Deletion LILRA6 Nasopharyngeal cancer
15 171484 3 168801287 168851758 Amplification EVI1 Nasopharyngeal cancer
16 171493 3 168867391 169381563 Amplification MDS1 Nasopharyngeal cancer
17 177937 3 65166887 65190844 Deletion Nasopharyngeal cancer
18 197433 5 176843000 176857208 Deletion LMP1 Nasopharyngeal cancer
19 205127 6 121025447 121050579 Deletion Nasopharyngeal cancer
20 210827 6 31463047 31563588 Deletion HCG26 Nasopharyngeal cancer
21 210828 6 31463047 31563588 Deletion HCP5 Nasopharyngeal cancer
22 210829 6 31463047 31563588 Deletion MICA Nasopharyngeal cancer
23 210832 6 31463297 31559455 Deletion HCG26 Nasopharyngeal cancer
24 210836 6 31463297 31559455 Deletion HCP5 Nasopharyngeal cancer
25 210840 6 31463297 31559455 Deletion MICA Nasopharyngeal cancer
26 212636 6 4007991 32935606 Deletion LMP2 Nasopharyngeal cancer
27 220654 7 140736 180194 Duplication CCDC146 Nasopharyngeal cancer
28 220655 7 140736 180194 Duplication LOC100132832 Nasopharyngeal cancer
29 220656 7 140736 180194 Duplication LOC100133091 Nasopharyngeal cancer
30 220657 7 140736 180194 Duplication PMS2L11 Nasopharyngeal cancer
31 220658 7 140736 180194 Duplication POMZP3 Nasopharyngeal cancer
32 222456 7 152200000 154700000 Duplication Nasopharyngeal cancer
33 222457 7 152200000 154700000 Duplication Nasopharyngeal cancer
34 222532 7 153118877 153284978 Duplication Nasopharyngeal cancer
35 222533 7 153118877 153284978 Duplication Nasopharyngeal cancer
36 224029 7 2721151 3758564 Duplication CARD11 Nasopharyngeal cancer
37 224030 7 2721151 3758564 Duplication GNA12 Nasopharyngeal cancer
38 227304 7 66680598 66860844 Deletion AR Nasopharyngeal cancer
39 229234 7 892539 3753994 Duplication Nasopharyngeal cancer
40 236340 8 15447307 15475846 Deletion TUSC3 Nasopharyngeal cancer
41 256863 9 9780222 9786577 Deletion Nasopharyngeal cancer

Expression for Nasopharyngeal Carcinoma

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.

Pathways for Nasopharyngeal Carcinoma

Pathways related to Nasopharyngeal Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

Pathways related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 TP53 PIK3CA NRAS NFKBIA HRAS
2 12.79 TP53 PIK3CA NRAS NFKBIA HRAS
3
Show member pathways
12.64 TP53 PIK3CA NRAS NFKBIA HRAS
4
Show member pathways
12.63 TP53 PIK3CA NRAS NFKBIA HRAS
5
Show member pathways
12.61 TP53 PIK3CA NRAS NFKBIA HRAS
6
Show member pathways
12.46 TP53 PIK3CA NRAS HRAS
7
Show member pathways
12.46 TP53 PIK3CA NRAS HRAS
8
Show member pathways
12.44 PIK3CA NRAS NFKBIA HRAS
9
Show member pathways
12.43 TP53 PIK3CA NRAS NFKBIA HRAS
10
Show member pathways
12.4 PIK3CA NRAS NFKBIA HRAS
11
Show member pathways
12.37 PIK3CA NRAS NFKBIA HRAS
12
Show member pathways
12.34 PIK3CA NRAS NFKBIA HRAS
13
Show member pathways
12.33 TP53 PIK3CA NFKBIA HRAS
14
Show member pathways
12.26 TP53 PIK3CA NFKBIA HRAS
15 12.23 TP53 PIK3CA NRAS HRAS
16
Show member pathways
12.21 TP53 NRAS NFKBIA HRAS
17
Show member pathways
12.19 PIK3CA NRAS NFKBIA HRAS
18
Show member pathways
12.19 TP53 PIK3CA NRAS NFKBIA HRAS
19
Show member pathways
12.11 PIK3CA NRAS NFKBIA HRAS
20
Show member pathways
12.1 PIK3CA NRAS NFKBIA HRAS
21
Show member pathways
12.07 TP53 PIK3CA NRAS HRAS
22 12.06 TP53 PIK3CA NRAS NFKBIA HRAS
23
Show member pathways
12.04 PIK3CA NRAS HRAS
24 12.04 TP53 PIK3CA NRAS HRAS
25
Show member pathways
12 TP53 PIK3CA NRAS HRAS
26
Show member pathways
11.99 PIK3CA NRAS NFKBIA HRAS
27 11.96 TP53 PIK3CA NRAS NFKBIA HRAS
28
Show member pathways
11.91 PIK3CA NRAS HRAS
29 11.87 PIK3CA NRAS HRAS
30 11.86 TP53 PIK3CA NRAS HRAS
31 11.83 TP53 PIK3CA NRAS HRAS
32 11.82 TP53 PIK3CA NFKBIA
33
Show member pathways
11.82 PIK3CA NRAS HRAS
34
Show member pathways
11.8 PIK3CA NRAS HRAS
35 11.79 TP53 PIK3CA NRAS HRAS
36
Show member pathways
11.75 PIK3CA NRAS HRAS
37 11.68 TP53 NRAS HRAS
38 11.64 TP53 NRAS HRAS
39 11.62 TP53 PIK3CA HRAS
40 11.59 PIK3CA NRAS HRAS
41 11.59 TP53 PIK3CA NRAS MIR29C MIR100 HRAS
42 11.3 TP53 PIK3CA NRAS HRAS
43
Show member pathways
11.15 PIK3CA NFKBIA HRAS
44 11.06 PIK3CA NRAS HRAS
45 10.83 PIK3CA NFKBIA
46 10.79 NRAS HRAS
47 10.21 TP53 LINC-ROR HOTAIR

GO Terms for Nasopharyngeal Carcinoma

Biological processes related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.26 TP53 MIR29C HRAS CDKN2B-AS1
2 Ras protein signal transduction GO:0007265 8.8 TP53 NRAS HRAS

Sources for Nasopharyngeal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....